Limits...
Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study.

Mahner S, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N, Hasenburg A, Sehouli J, Habermann A, Hillemanns P, Fuerst S, Strauss HG, Baumann K, Thiel F, Mustea A, Meier W, du Bois A, Griebel LF, Woelber L, AGO-CaRE 1 investigato - J. Natl. Cancer Inst. (2015)

Bottom Line: The three-year progression-free survival (PFS) rate of N+ patients was 35.2%, and the overall survival (OS) rate 56.2% compared with 75.2% and 90.2% in node-negative patients (N-).This effect was statistically significant in multivariable analysis adjusted for age, Eastern Cooperative Oncology Group, Union internationale contre le cancer stage, grade, invasion depth, and number of positive nodes (PFS: HR = 0.58, 95% CI = 0.43 to 0.78, P < .001; OS: HR = 0.63, 95% CI = 0.43 to 0.91, P = .01).Adjuvant chemoradiation could be a possible strategy to improve therapy because it is superior to radiotherapy alone in other squamous cell carcinomas.

View Article: PubMed Central - PubMed

Affiliation: Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (SM, LFG, LW); Department of Obstetrics and Gynecology, University Hospital Munich Maistrasse, Munich, Germany (JJ); Department of Obstetrics and Gynecology, University Medical Center Kiel, Kiel, Germany (FH); KKS Philipps University Marburg, Marburg, Germany (PN); Department of Gynecology and Gynecologic Oncology Kliniken Essen-Mitte, Essen, Germany (PH, AdB); Department of Obstetrics and Gynecology, University of Ulm Medical Center, Ulm, Germany (NdG); Department of Gynecology and Gynecologic Oncology, University Hospital Freiburg, Freiburg, Germany (AHas); Department of Gynecology, Charité University Medicine Berlin Campus Virchow, Berlin, Germany (JS); Department of Obstetrics and Gynecology, University Hospital Magdeburg, Magdeburg, Germany (AHab); Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany (PH); Department of Obstetrics and Gynecology, Grosshadern University Hospital, Munich, Germany (SF); Department of Gynecology, University Hospital Halle, Halle, Germany (HGS); Department of Gynecology and Gynecologic Oncology, Philipps University Marburg, Marburg, Germany (KB); Department of Gynecology, University Hospital Erlangen, Erlangen, Germany (FT); Department of Obstetrics and Gynecology, University Hospital Greifswald, Greifswald, Germany (AM); Department of Obstetrics and Gynecology, Evangelical Hospital Duesseldorf, Duesseldorf, Germany (WM).

Show MeSH

Related in: MedlinePlus

Lymph node status and outcome. A) Progression-free survival. B) overall survival. P values were calculated using the two-sided log-rank test. CI = confidence interval; HR = hazard ratio; N- = node-negative; N+ = node-positive; OS = overall survival; PFS = progression-free survival.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4356703&req=5

Figure 2: Lymph node status and outcome. A) Progression-free survival. B) overall survival. P values were calculated using the two-sided log-rank test. CI = confidence interval; HR = hazard ratio; N- = node-negative; N+ = node-positive; OS = overall survival; PFS = progression-free survival.

Mentions: Three-year progression-free survival (PFS) rate of N+ patients was 35.2%, compared with 75.2% in N- patients (P < .001) (Figure 2A); three-year overall survival (OS) rates were 56.2% and 90.2%, respectively (P < .001) (Figure 2B). Altogether 267 of 1249 patients died, 136 (50.9%) clearly disease related; 87 of 267 (32.6%) deaths were indicated as “death from unknown cause,” and 44 of 267 (16.5%) as “death from other causes.” Of these 131 not clearly disease-related deaths, 72 occurred in the N+ and 59 in the N- cohort.


Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study.

Mahner S, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N, Hasenburg A, Sehouli J, Habermann A, Hillemanns P, Fuerst S, Strauss HG, Baumann K, Thiel F, Mustea A, Meier W, du Bois A, Griebel LF, Woelber L, AGO-CaRE 1 investigato - J. Natl. Cancer Inst. (2015)

Lymph node status and outcome. A) Progression-free survival. B) overall survival. P values were calculated using the two-sided log-rank test. CI = confidence interval; HR = hazard ratio; N- = node-negative; N+ = node-positive; OS = overall survival; PFS = progression-free survival.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4356703&req=5

Figure 2: Lymph node status and outcome. A) Progression-free survival. B) overall survival. P values were calculated using the two-sided log-rank test. CI = confidence interval; HR = hazard ratio; N- = node-negative; N+ = node-positive; OS = overall survival; PFS = progression-free survival.
Mentions: Three-year progression-free survival (PFS) rate of N+ patients was 35.2%, compared with 75.2% in N- patients (P < .001) (Figure 2A); three-year overall survival (OS) rates were 56.2% and 90.2%, respectively (P < .001) (Figure 2B). Altogether 267 of 1249 patients died, 136 (50.9%) clearly disease related; 87 of 267 (32.6%) deaths were indicated as “death from unknown cause,” and 44 of 267 (16.5%) as “death from other causes.” Of these 131 not clearly disease-related deaths, 72 occurred in the N+ and 59 in the N- cohort.

Bottom Line: The three-year progression-free survival (PFS) rate of N+ patients was 35.2%, and the overall survival (OS) rate 56.2% compared with 75.2% and 90.2% in node-negative patients (N-).This effect was statistically significant in multivariable analysis adjusted for age, Eastern Cooperative Oncology Group, Union internationale contre le cancer stage, grade, invasion depth, and number of positive nodes (PFS: HR = 0.58, 95% CI = 0.43 to 0.78, P < .001; OS: HR = 0.63, 95% CI = 0.43 to 0.91, P = .01).Adjuvant chemoradiation could be a possible strategy to improve therapy because it is superior to radiotherapy alone in other squamous cell carcinomas.

View Article: PubMed Central - PubMed

Affiliation: Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (SM, LFG, LW); Department of Obstetrics and Gynecology, University Hospital Munich Maistrasse, Munich, Germany (JJ); Department of Obstetrics and Gynecology, University Medical Center Kiel, Kiel, Germany (FH); KKS Philipps University Marburg, Marburg, Germany (PN); Department of Gynecology and Gynecologic Oncology Kliniken Essen-Mitte, Essen, Germany (PH, AdB); Department of Obstetrics and Gynecology, University of Ulm Medical Center, Ulm, Germany (NdG); Department of Gynecology and Gynecologic Oncology, University Hospital Freiburg, Freiburg, Germany (AHas); Department of Gynecology, Charité University Medicine Berlin Campus Virchow, Berlin, Germany (JS); Department of Obstetrics and Gynecology, University Hospital Magdeburg, Magdeburg, Germany (AHab); Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany (PH); Department of Obstetrics and Gynecology, Grosshadern University Hospital, Munich, Germany (SF); Department of Gynecology, University Hospital Halle, Halle, Germany (HGS); Department of Gynecology and Gynecologic Oncology, Philipps University Marburg, Marburg, Germany (KB); Department of Gynecology, University Hospital Erlangen, Erlangen, Germany (FT); Department of Obstetrics and Gynecology, University Hospital Greifswald, Greifswald, Germany (AM); Department of Obstetrics and Gynecology, Evangelical Hospital Duesseldorf, Duesseldorf, Germany (WM).

Show MeSH
Related in: MedlinePlus